文献速递中药与中成药合理使用中医内科

人参作为器官纤维化疾病潜在治疗药物的研究综述

Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.
PubMed 文献 · Chin Med · 2020-11-24

该综述以人参(Panax ginseng C. A. Meyer)为对象,先概括纤维化的分子机制与常用治疗方法,再系统总结人参提取物及复方治疗肝、肺、心肌和肾纤维化的研究进展,并介绍人参中具有抗纤维化活性的单体成分及其治疗前景与局限。

要点

  • 人参提取物、复方及单体可抑制细胞外基质过度沉积,对纤维化器官有保护作用。
  • 转化生长因子β信号转导等分子机制已获证实,但多组分协同靶点仍待探索。
  • 需开展临床试验评价人参与常用抗纤维化药物联合应用的可行性。

核心结论

  • 人参可被视为一种有价值的抗纤维组织增生草药,其提取物、衍生复方和单体通过抑制反复损伤导致的细胞外基质大量沉积来保护纤维化器官。
  • 尽管转化生长因子β信号转导等分子机制已被证实,未来研究仍需探索人参治疗纤维化疾病包括多组分协同作用治疗靶点在内的潜在机制。
  • 有必要开展临床试验评价人参与常用纤维化药物联合应用的可行性。

研究设计与样本

  • 本文为综述,概括纤维化的分子机制与常用治疗方法,并系统总结人参提取物及复方治疗肝纤维化、肺纤维化、心肌纤维化和肾纤维化的研究进展。
  • 文中还描述了从人参中分离的活性成分及其突出的抗纤维化特性,并揭示人参在纤维化疾病中的潜在治疗前景与局限性。

主要发现

  • 人参提取物、衍生复方和单体可抑制由反复损伤引起的细胞外基质大量沉积,为纤维化器官提供保护。
  • 转化生长因子β信号转导等分子机制已获证实。
  • 从人参中分离的活性成分具有突出的抗纤维化特性。

临床怎么用

  • 可关注人参提取物、复方及单体在肝、肺、心肌、肾纤维化中的潜在应用,但联合常用纤维化药物的可行性尚待临床试验评价。
  • 临床应用时应认识到多组分协同作用的治疗靶点尚未阐明,机制层面仍需进一步研究。

局限性

  • 人参治疗纤维化疾病的多组分协同作用机制及治疗靶点尚未明确,需未来研究探索。
  • 尚需开展临床试验评价人参与常用纤维化药物联合应用的可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ginseng (Panax ginseng C. A. Meyer), a representative Chinese herbal medicine, can improve the body's antioxidant and anti-inflammatory capacity. Recently, scientists have shifted emphasis towards the initial stages of different malignant diseases-corresponding organ fibrosis and explored the essential role of P. ginseng in the treatment of fibrotic diseases. MAIN BODY: In the first instance, the review generalizes the molecular mechanisms and common therapeutic methods of fibrosis. Next, due to the convenience and safety of individual medication, the research progress of ginseng extract and formulas in treating liver fibrosis, pulmonary fibrosis, myocardial fibrosis, and renal fibrosis has been systematically summarized. Finally, we describe active ingredients isolated from P. ginseng for their outstanding anti-fibrotic properties and further reveal the potential therapeutic prospect and limitations of P. ginseng in fibrotic diseases. CONCLUSIONS: P. ginseng can be regarded as a valuable herbal medicine against fibrous tissue proliferation. Ginseng extract, derived formulas and monomers can inhibit the abundant deposition of extracellular matrix which caused by repeated damage and provide protection for fibrotic organs. Although the molecular mechanisms such as transforming growth factor β signal transduction have been confirmed, future studies should still focus on exploring the underlying mechanisms of P. ginseng in treating fibrotic disease including the therapeutic targets of synergistic action of multiple components in P. ginseng. Moreover, it is also necessary to carry out clinical trial to evaluate the feasibility of P. ginseng in combination with common fibrosis drugs.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Liu H, Lv C, Lu J, et al. Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease. Chin Med. 2020. PMID: 33292321. doi:10.1186/s13020-020-00400-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。